These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4034583)

  • 1. Pharmacology and clinical studies with RU 23908 (Anandron).
    Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
    Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
    Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F
    Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 6. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H
    Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
    Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP
    Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549
    [No Abstract]   [Full Text] [Related]  

  • 9. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

  • 12. Design of antiandrogens and their mechanisms of action: a case study (anandron).
    Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
    Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen blockade in prostate cancer.
    Labrie F; Candas B
    Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
    [No Abstract]   [Full Text] [Related]  

  • 14. The kinetics of antiandrogens in humans.
    Tremblay D; Dupront A; Meyer BH; Pottier J
    Prog Clin Biol Res; 1987; 243A():341-50. PubMed ID: 2958859
    [No Abstract]   [Full Text] [Related]  

  • 15. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
    Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
    [No Abstract]   [Full Text] [Related]  

  • 17. The place and the results of monotherapy.
    Bonnet P
    Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
    [No Abstract]   [Full Text] [Related]  

  • 18. Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues.
    Raynaud JP; Bonne C; Bouton MM; Lagace L; Labrie F
    J Steroid Biochem; 1979 Jul; 11(1A):93-9. PubMed ID: 385986
    [No Abstract]   [Full Text] [Related]  

  • 19. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 20. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.